Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
LEO Pharma to acquire Bayer’s prescription dermatology unit
August 1, 2018

LEO Pharma A/S is about to expand its lead in medical dermatology with the acquisition of Bayer’s prescription dermatology unit. The portfolio to be acquired includes branded topical prescription treatments for acne, fungal skin infections and rosacea, and a range of topical steroids. The business division has approximately 450 employees and reported an annual turnover in 2017 of more than EUR 280m. The purchasing price is around EUR 1bn according to sources mentioned in Borsen.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: